Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Opthea (OPT) announced updates on its Phase 3 clinical program, including the termination of COAST and accelerated topline results from its ...

(RTTNews) - Opthea Limited (OPT, OPT.AX) announced its decision to discontinue the development of sozinibercept for wet age-related macular degeneration or wet AMD. This follows the negative ...

After announcing that lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD), Opthea has now decided to close the Coast trial as well as ...

The global ShORe Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 0.5 mg ranibizumab every four weeks ...

Broker Canaccord Genuity says this ASX share potentially 'has no value from here'. Here's what is happening with this healthcare stock.

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...